LRRK2 ASO for Parkinson’s: Phase 1 Trial Results
Promising New Treatment Shows Positive Results in Parkinson’s Disease Clinical Trial In a significant step forward for Parkinson’s disease research, a first-in-human clinical trial has demonstrated the safety and potential efficacy of an experimental treatment targeting the LRRK2 protein. The trial, focused on the antisense oligonucleotide BIIB094, revealed that the drug was well-tolerated by participants … Read more